The stock of Huaneng Power International Inc (ADR) (NYSE:HNP) gapped down by $1.02 today and has $26.30 target or 6.00% below today’s $27.98 share price. The 5 months technical chart setup indicates high risk for the $14.47 billion company. The gap down was reported on Mar, 22 by Barchart.com. If the $26.30 price target is reached, the company will be worth $868.20M less. About 99,347 shares traded or 58.30% up from the average. Huaneng Power International Inc (ADR) (NYSE:HNP) has risen 10.32% since August 15, 2016 and is uptrending. It has outperformed by 3.30% the S&P500.
Among 9 analysts covering Acceleron Pharma (NASDAQ:XLRN), 7 have Buy rating, 0 Sell and 2 Hold. Therefore 78% are positive. Acceleron Pharma had 14 analyst reports since August 13, 2015 according to SRatingsIntel. The stock of Acceleron Pharma Inc (NASDAQ:XLRN) has “Outperform” rating given on Monday, January 18 by FBR Capital. Credit Suisse initiated Acceleron Pharma Inc (NASDAQ:XLRN) on Thursday, January 21 with “Outperform” rating. Oppenheimer reinitiated the shares of XLRN in report on Monday, February 1 with “Outperform” rating. Barclays Capital initiated the shares of XLRN in report on Wednesday, April 27 with “Overweight” rating. The rating was initiated by Janney Capital with “Neutral” on Thursday, December 17. The stock of Acceleron Pharma Inc (NASDAQ:XLRN) earned “Outperform” rating by Oppenheimer on Tuesday, December 13. As per Friday, November 20, the company rating was initiated by Oppenheimer. Barclays Capital maintained the shares of XLRN in report on Monday, June 13 with “Overweight” rating. The rating was maintained by FBR Capital on Friday, January 15 with “Outperform”. The rating was initiated by Citigroup with “Neutral” on Thursday, September 29. See Acceleron Pharma Inc (NASDAQ:XLRN) latest ratings:
14/03/2017 Broker: JP Morgan Rating: Neutral New Target: $33.00 Initiates Coverage On
02/03/2017 Broker: Nomura Rating: Buy Initiates Coverage On
02/03/2017 Broker: Citigroup Old Rating: Neutral New Rating: Buy Old Target: $40.00 New Target: $36.00 Upgrade
13/12/2016 Broker: Oppenheimer Rating: Outperform Initiate
29/09/2016 Broker: Citigroup Rating: Neutral New Target: $40 Initiate
Among 3 analysts covering Huaneng Power International (NYSE:HNP), 0 have Buy rating, 1 Sell and 2 Hold. Therefore 0 are positive. Huaneng Power International had 3 analyst reports since August 5, 2015 according to SRatingsIntel. Macquarie Research downgraded the stock to “Neutral” rating in Tuesday, May 31 report. On Wednesday, August 5 the stock rating was downgraded by Deutsche Bank to “Hold”. Citigroup downgraded the stock to “Sell” rating in Monday, April 18 report.
Huaneng Power International, Inc. is an independent power producer. The company has market cap of $14.47 billion. The Firm and its subsidiaries are engaged in the generation and sale of electric power to the respective regional or provincial grid companies in the People’s Republic of China (PRC) and in the Republic of Singapore (Singapore). It has a 6.6 P/E ratio. The Firm is engaged in developing, constructing, operating and managing power plants across China.
Analysts await Huaneng Power International Inc (ADR) (NYSE:HNP) to report earnings on March, 28.
Investors sentiment increased to 1.35 in Q4 2016. Its up 0.35, from 1 in 2016Q3. It is positive, as 21 investors sold Acceleron Pharma Inc shares while 34 reduced holdings. 25 funds opened positions while 49 raised stakes. 31.42 million shares or 3.11% more from 30.48 million shares in 2016Q3 were reported. Baker Bros Advsr Lp stated it has 28,765 shares. Credit Suisse Ag reported 0% in Acceleron Pharma Inc (NASDAQ:XLRN). Price T Rowe Assoc Md reported 3.72 million shares stake. Eagle Asset Management owns 1.17M shares. Sphera Funds Management Ltd has invested 0.65% in Acceleron Pharma Inc (NASDAQ:XLRN). Zurcher Kantonalbank (Zurich Cantonalbank) invested in 0% or 1,024 shares. Teacher Retirement Of Texas owns 79,912 shares. 46,400 were accumulated by Swiss Financial Bank. Moreover, Dupont Capital Management Corporation has 0.01% invested in Acceleron Pharma Inc (NASDAQ:XLRN). Jasper Ridge Prns Limited Partnership stated it has 62,105 shares or 0.11% of all its holdings. California State Teachers Retirement Sys stated it has 0% of its portfolio in Acceleron Pharma Inc (NASDAQ:XLRN). Blackrock Inc holds 0% or 78,860 shares. Bnp Paribas Arbitrage has invested 0% of its portfolio in Acceleron Pharma Inc (NASDAQ:XLRN). Tower Rech Ltd Liability (Trc) holds 0% or 993 shares. Novo A S has 3.01% invested in Acceleron Pharma Inc (NASDAQ:XLRN) for 1.24 million shares.
About 269,703 shares traded. Acceleron Pharma Inc (NASDAQ:XLRN) has declined 11.94% since August 15, 2016 and is downtrending. It has underperformed by 18.97% the S&P500.
